117 related articles for article (PubMed ID: 34020239)
21. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
22. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
[TBL] [Abstract][Full Text] [Related]
24. Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
Ahmed EY; Elserwy WS; El-Mansy MF; Serry AM; Salem AM; Abdou AM; Abdelrahman BA; Elsayed KH; Abd Elaziz MR
Bioorg Med Chem Lett; 2021 Sep; 48():128258. PubMed ID: 34246754
[TBL] [Abstract][Full Text] [Related]
25. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
26. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
27. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
28. 6-Shogaol enhances renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated cytochrome c release and down-regulation of c-FLIP(L) expression.
Han MA; Woo SM; Min KJ; Kim S; Park JW; Kim DE; Kim SH; Choi YH; Kwon TK
Chem Biol Interact; 2015 Feb; 228():69-78. PubMed ID: 25619640
[TBL] [Abstract][Full Text] [Related]
29. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
[TBL] [Abstract][Full Text] [Related]
30. Triiodothyronine regulates cell growth and survival in renal cell cancer.
Czarnecka AM; Matak D; Szymanski L; Czarnecka KH; Lewicki S; Zdanowski R; Brzezianska-Lasota E; Szczylik C
Int J Oncol; 2016 Oct; 49(4):1666-78. PubMed ID: 27632932
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
[TBL] [Abstract][Full Text] [Related]
33. AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.
Doñate F; Raitano A; Morrison K; An Z; Capo L; Aviña H; Karki S; Morrison K; Yang P; Ou J; Moriya R; Shostak Y; Malik F; Nadell R; Liu W; Satpayev D; Atkinson J; Joseph IB; Pereira DS; Challita-Eid PM; Stover DR
Clin Cancer Res; 2016 Apr; 22(8):1989-99. PubMed ID: 26589436
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, Assessment of Antineoplastic Activity, and Molecular Docking of Novel 2-Thioxo-oxazolidin-4-one Derivatives.
Ramalho EAVF; Viana DCF; Mendonça da Costa VC; Pitta M; Rêgo MJBM; Pitta IDR; Pitta MGDR
Med Chem; 2022; 18(9):980-989. PubMed ID: 35249500
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
36. Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.
Mohamed MF; Hassaneen HM; Elzayat EM; El-Hallouty SM; El-Manawaty M; Saleh FM; Mohamed Y; El-Zohiry D; Fahmy G; Abdelaal N; Hassanin N; Hossam N
Anticancer Agents Med Chem; 2019; 19(9):1141-1149. PubMed ID: 30843494
[TBL] [Abstract][Full Text] [Related]
37. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Lin SY; Chang CF; Coumar MS; Chen PY; Kuo FM; Chen CH; Li MC; Lin WH; Kuo PC; Wang SY; Li AS; Lin CY; Yang CM; Yeh TK; Song JS; Hsu JTA; Hsieh HP
Bioorg Chem; 2020 May; 98():103689. PubMed ID: 32171993
[TBL] [Abstract][Full Text] [Related]
38. New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies.
Abd El-Wahab HAA; Mansour HS; Ali AM; El-Awady R; Aboul-Fadl T
Bioorg Chem; 2022 Mar; 120():105622. PubMed ID: 35091290
[TBL] [Abstract][Full Text] [Related]
39. Telmisartan-Induced Cytotoxicity via G
Tsujiya Y; Hasegawa A; Yamamori M; Okamura N
Biol Pharm Bull; 2021; 44(12):1878-1885. PubMed ID: 34853271
[TBL] [Abstract][Full Text] [Related]
40. A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET.
Li J; Tan G; Cai Y; Liu R; Xiong X; Gu B; He W; Liu B; Ren Q; Wu J; Chi B; Zhang H; Zhao Y; Xu Y; Zou Z; Kang F; Xu K
Biochem Pharmacol; 2021 Aug; 190():114620. PubMed ID: 34043966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]